KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Net Income (2016 - 2025)

Jazz Pharmaceuticals has reported Net Income over the past 15 years, most recently at $203.5 million for Q4 2025.

  • Quarterly results put Net Income at $203.5 million for Q4 2025, up 6.47% from a year ago — trailing twelve months through Dec 2025 was -$263.5 million (down 146.91% YoY), and the annual figure for FY2025 was -$355.5 million, down 163.28%.
  • Net Income for Q4 2025 was $203.5 million at Jazz Pharmaceuticals, down from $251.5 million in the prior quarter.
  • Over the last five years, Net Income for JAZZ hit a ceiling of $251.5 million in Q3 2025 and a floor of -$718.4 million in Q2 2025.
  • Median Net Income over the past 5 years was $70.4 million (2023), compared with a mean of $9.1 million.
  • Biggest five-year swings in Net Income: tumbled 641.93% in 2022 and later soared 1108.6% in 2023.
  • Jazz Pharmaceuticals' Net Income stood at -$32.3 million in 2021, then tumbled by 641.93% to -$240.0 million in 2022, then soared by 139.42% to $94.6 million in 2023, then surged by 102.0% to $191.1 million in 2024, then increased by 6.47% to $203.5 million in 2025.
  • The last three reported values for Net Income were $203.5 million (Q4 2025), $251.5 million (Q3 2025), and -$718.4 million (Q2 2025) per Business Quant data.